Skip to content

Brain Activity During Complex Walking in People With Atypical Parkinsonian Syndromes

Walking and Thinking - Brain Activity During Complex Walking in Atypical Parkinsonian Syndromes

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06906276
Enrollment
30
Registered
2025-04-02
Start date
2025-03-14
Completion date
2027-12-31
Last updated
2025-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aging, Atypical Parkinson Disease, fNIRS, Gait Disorders, Neurologic

Brief summary

Every-day life means being part of a complex environment and performing complex tasks that usually involve a combination of motor and cognitive skills. However, the process of aging or the sequelae of neurological diseases such as atypical Parkinson's disease (APD) compromises motor-cognitive interaction necessary for an independent lifestyle. While motor-cognitive performance has been identified as an important goal for sustained health across different clinical populations, little is known about underlying brain function leading to these difficulties and how to best target these motor-cognitive difficulties in the context of rehabilitation and exercise interventions. The challenge of improving treatments of motor-cognitive difficulties (such as dual-tasking and navigation) is daunting, and an important step is arriving at a method that accurately portrays these impairments in an ecologically valid state. The investigators aim therefore to explore brain function during complex walking in healthy and APD by investigating the effects of age and neurological disease on motor-cognitive performance and its neural correlates during three conditions of complex walking (dual-task walking, navigation and a combination of both) using non-invasive measures of brain activity (functional near infrared spectrometry, fNIRS) and advanced gait analysis in real time in older healthy adults and people with APD.

Interventions

OTHERAssessment of brain activity with fNIRS and behavioural assessments (motor, motor-cognitive and cognitive) during three complex walking conditions.

Dual-task walking with the auditory stroop task. Navigational walking - a course consisting of a distribution of 45 and 90 degrees turns to the left and right Navigational and dual-task walking (condition 1 and 2 together)

Sponsors

Karolinska University Hospital
CollaboratorOTHER
Karolinska Institutet
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* clinical diagnosis of PSP according to Movement Disorder Society (MDS) (2017) or * MSA according to MDS criteria (2022) * the ability to walk with or without a mobility device for ≤5 minutes continuously

Exclusion criteria

* cognitive difficulties affecting the ability to understand and/or follow verbal/written - instructions * severe freezing of gait * Severe hearing or visual impairments that affect participation in the assessments * Other neurological diseases * Other diseases that can affect gait or balance.

Design outcomes

Primary

MeasureTime frameDescription
Functional near infrared spectrometry (fNIRS)BaselineThe measurement of changes in concentration of HbO and HHb in the prefrontal cortex will be assessed using a NIRSPORT 2 (NIRx Medizintechnik, Berlin, Germany) device.
Gait performance during all conditionsBaselineGait variables such as stride time and/or velocity will be analyzed with the APDM mobility system.
Dual-task performance-reaction timeBaselineCognitive performance of the dual task will be assessed as errors in the response to the Auditory Stroop task.

Secondary

MeasureTime frameDescription
Cognitive function - Attention and psychomotor processing speedBaselineAttention and psychomotor processing speed will be assessed with the Trail Making Test (TMT) from D-KEFS (Delis-Kaplan Executive Function System).
Cognitive function - Episodic memoryBaselineEpisodic memory will be assessed with the Ray Auditory Verbal Learning Test (RAVLT).
Cognitive function - Inhibition & task-set switchingBaselineInhibition & task-set switching with the Color-Word Interference Test (CWIT) from D-KEFS (Delis-Kaplan Executive Function System)
Self-reported level of physical activityBaselineAssessed with the Frändin-Grimby Scale (score 1-6, higher score=better)
Physical activityBaselineAssessed with accelerometers (Actigraph GT3X+) for seven consecutive days after the clinical visit
Resting-state functional near infrared spectrometry (rsfNIRS)BaselineThe measurement of changes in concentration of HbO and HHb in the whole cortex will be assessed using a NIRSPORT 2 (NIRx Medizintechnik, Berlin, Germany) device during 2x 10min of rest, while seated in a comfortable chair.
Balance performanceBaselineAssessed with the Mini-BESTest (Balance Evaluation Systems test), 0-28p,
Anxiety and depressionBaselineAssessed with Hospital Anxiety and Depression Scale (HADS), 0-24 on the depression and anxiety part respectively. Lower score=better
Walking abilityBaselineSelf-assessed walking ability with the WALK-12G.
Dual-task performance -errorsBaselineCognitive performance of the dual task will be assessed as the reaction time to respond during the Auditory Stroop
DisabilityBaselineWHO Disability Assessment Schedule (WHODAS) version 2.0, 12 self-assessed questions (12 to 60) more points=worse
Motor function/disease severityBaselineAssessed with the movement Disorders Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Higher scores = worse/more symptoms
Cognitive function- composite scoreBaselineThe cognitive test battery comprised the following tests: The Color-Word Interference Test (CWIT), Verbal Fluency, Trail Making Test (TMT), Ray Auditory Verbal Learning Test (RAVLT), and Symbol Digit Modalities Test (SDMT). Cognitive function will be assessed as a composite measure of these tests together.
Cognitive function - verbal fluencyBaselineVerbal function, initiation & task-set switching with the Verbal Fluency test from D-KEFS (Delis-Kaplan Executive Function System).

Countries

Sweden

Contacts

Primary ContactCompliance Office Karolinska Insitutet
compliance@ki.se+46852480000
Backup ContactErika Franzén, Prof,
erika.franzen@ki.se+46852488878

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026